|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in diagnosis,treatment and palliation of cholangiocarcinoma:1990-2009显示文摘Several advances in diagnosis,treatment and palliation of cholangiocarcinoma(CC)have occurred in the last decades.A multidisciplinary approach to this disease is therefore recommended.CC is a relatively rare tumor and the main risk factors are:chronic inflammation, genetic predisposition and congenital abnormalities of the biliary tree.While the incidence of intra-hepatic CC is increasing,the incidence of extra-hepatic CC is trending down.The only curative treatment for CC is surgical resection with negative margins.Liver transplantation has been proposed only for selected patients with hilar CC that cannot be resected who have no metastatic disease after a period of neoadjuvant chemo-radiation therapy.Magnetic resonance imaging/magnetic resonance cholangiopancreatography,positron emission tomography scan,endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging.Adjuvant therapy,palliative chemotherapy and radiotherapy have been relatively ineffective for inoperable CC.For most of these patients biliary stenting provides effective palliation.Photodynamic therapy is an emerging palliative treatment that seems to provide pain relief,improve biliary patency and increase survival. The clinical utility of other emerging therapies such as transarterial chemoembolization,hepatic arterial chemoinfusion and high intensity intraductal ultrasound needs further study. | Murad Aljiffry Mark J Walsh Michele Molinari | 2009 | World Journal of Gastroenterology2009，15，34： | 82 |
| 2 | Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010显示文摘Several advances in genetics, diagnosis and palliation of pancreatic cancer (PC) have occurred in the last decades. A multidisciplinary approach to this disease is therefore recommended. PC is relatively common as it is the fourth leading cause of cancer related mortality. Most patients present with obstructive jaundice, epigastric or back pain, weight loss and anorexia. Despite improvements in diagnostic modalities, the majority of cases are still detected in advanced stages. The only curative treatment for PC remains surgical resection. No more than 20% of patients are candidates for surgery at the time of diagnosis and survival remains quite poor as adjuvant therapies are not very effective. A small percentage of patients with borderline non-resectable PC might benefit from neo-adjuvant chemoradiation therapy enabling them to undergo resection; however, randomized controlled studies are needed to prove the benefits of this strategy. Patients with unresectable PC benefit from palliative interventions such as biliary decompression and celiac plexus block. Further clinical trials to evaluate new chemo and radiation protocols as well as identification of genetic markers for PC are needed to improve the overall survival of patients affected by PC, as the current overall 5-year survival rate of patients affected by PC is still less than 5%. The aim of this article is to review the most recent high quality literature on this topic. | Chakshu Sharma Karim M Eltawil Paul D Renfrew Mark J Walsh Michele Molinari | 2011 | World Journal of Gastroenterology2011，17，7： | 28 |
| 3 | Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases显示文摘Polycystic liver diseases(PLD)represent a group of genetic disorders in which cysts occur in the liver(autosomal dominant polycystic liver disease)or in combination with cysts in the kidneys(autosomal dominant polycystic kidney disease).Regardless of the genetic mutations,the natural history of these disorders is alike.The natural history of PLD is characterized by a continuous increase in the volume and the number of cysts.Both genders are affected;however,women have a higher prevalence.Most patients with PLD are asymptomatic and can be managed conservatively.Severe symptoms can affect 20%of patients who develop massive hepatomegaly with compression of the surrounding organs.Rrarely,patients with PLD suffer from acutecomplications caused by the torsion of hepatic cysts,intraluminal cystic hemorrhage and infections.The most common methods for the diagnosis of PLD are cross sectional imaging studies.Abdominal ultrasound and computerized tomography are the two most frequently used investigations.Magnetic resonance imaging is more sensitive and specific,and it is a valuable test for patients with intravenous contrast allergies or renal dysfunction.Different treatment modalities are available to physicians caring for these patients.Medical treatment has been ineffective.Percutaneous sclerotherapy,transarterial embolization,cyst fenestration,hepatic resection and liver transplantation are indicated to specific groups of patients and have to be tailored according to the extent of disease.This review outlines the current knowledge of the pathophysiology,clinical course,diagnosis and treatment strategies of PLD. | Bassam Abu-Wasel Caolan Walsh Valerie Keough Michele Molinari | 2013 | World Journal of Gastroenterology2013，19，35： | 10 |
| 4 | Rifaximin vs conventional oral therapy for hepatic encephalopathy:A meta-analysis显示文摘AIM: To characterize the efficacy of rifaximin in the management of hepatic encephalopathy (HE) as several randomized controlled studies have shown contradictory results on its effectiveness in comparison to other oral agents. METHODS: We performed a systematic review and random effects meta-analysis of all eligible trials identifi ed through electronic and manual searches. Twelve randomized controlled trials met the inclusion criteria with a total of 565 patients. RESULTS: The clinical effectiveness of rifaximin was equivalent to disaccharides or other oral antibiotics[odds ratio (OR) 0.96; 95% CI: 0.94-4.08] but with a better safety profi le (OR 0.27; 95% CI: 0.12-0.59). At the completion of treatment protocols, patients receiving rifaximin showed lower serum ammonia levels [weighted mean difference (WMD) = -10.65; 95% CI: -23.4-2.1; P = 0.10], better mental status (WMD = -0.24; 95% CI: -0.57-0.08; P = 0.15) and less asterixis (WMD -0.1; 95% CI -0.26-0.07; P = 0.25) without reaching statistical signifi cance. On the other hand, other psychometric outcomes such as electroencephalographic response and grades of portosystemic encephalopathy were superior in patients treated with rifaximin in comparison to the control group (WMD = 0.21, 95% CI: -0.33-0.09, P = 0.0004; and WMD = -2.33, 95% CI: -2.68-1.98, P = 0.00001, respectively). Subgroup and sensitivity analysis did not show any signifi cant difference in the above fi ndings. CONCLUSION: Rifaximin appears to be at least as effective as other conventional oral agents for the treatment of HE with a better safety profi le. | Karim M Eltawil Marie Laryea Kevork Peltekian Michele Molinari | 2012 | World Journal of Gastroenterology2012，18，8： | 9 |
| 5 | Adhesive wear mechanisms uncovered by atomistic simulations显示文摘In this review, we discuss our recent advances in modeling adhesive wear mechanisms using coarse-grained atomistic simulations. In particular, we present how a model pair potential reveals the transition from ductile shearing of an asperity to the formation of a debris particle. This transition occurs at a critical junction size, which determines the particle size at its birth. Atomistic simulations also reveal that for nearby asperities, crack shielding mechanisms result in a wear volume proportional to an effective area larger than the real contact area. As the density of microcontacts increases with load, we propose this crack shielding mechanism as a key to understand the transition from mild to severe wear. We conclude with open questions and a road map to incorporate these findings in mesoscale continuum models. Because these mesoscale models allow an accurate statistical representation of rough surfaces, they provide a simple means to interpret classical phenomenological wear models and wear coefficients from physics-based principles. | Jean-Fran?ois MOLINARI Ramin AGHABABAEI Tobias BRINK Lucas FRéROT Enrico MILANESE | 2018 | Friction2018，6，3： | 6 |
| 6 | Early Versus Late Drain Removal After Standard Pancreatic Resections: Results of a Prospective Randomized Trial显示文摘 | Claudio Bassi Enrico Molinari Giuseppe Malleo Stefano Crippa Giovanni Butturini Roberto Salvia Giorgio Talamini Paolo Pederzoli | 2010 | Annals of Surgery2010，，2： | 5 |
| 7 | Brazilian biosafety law and the new breeding technologies显示文摘Globally,the area of land cultivated with genetically modified(GM)crops has increased a thousand-fold over the last two decades.Although this technology has become important for food production,the regulatory frameworks that underpin these outcomes are based on a list of requirements for a risk assessment that differ from country to country.In recent years,policymakers have had the opportunity to learn from the controversies over transgenics to create effective regulatory milestones for emerging technologies,allowing them to reach their potential for a more sustainable agriculture,ensuring food security.In Brazil,Law No.11.105 of 24 March 2005 established a framework with four main organizations responsible for risk assessment and management.However,most of new breeding technologies did not exist at that time and were not considered in this law.In2016,Normative Resolution No.16 of the National Biosafety Technical Commission(CTNBio)was established to address this gap based on the evaluation of the products obtained through these techniques(termed Innovative Precision Improvement Techniques in the resolution),in a case-by-case consultation system.Briefly,if the product is designated to be a GM,the developer will have to go through the biosafety requirements and will be approved only after CTNBio risk assessment.If the product is designated not to be GM(for the purposes of the legislation),then it can be registered using the existing procedures.Currently,152 GM products are commercially approved in Brazil.In 2018,CTNBio assessed the first consultation on commercial release of plants generated using the new breeding technologies and has subsequently approved six products.It is expected that many institutions would be able to participate in Brazilian and world markets,developing and introducing new biotechnological solutions and products through a more sustainable approach and without facing public disapproval,a common issue for GM crops. | Alexandre Lima NEPOMUCENO Renata FUGANTI-PAGLIARINI Maria Sueli Soares FELIPE Hugo Bruno Correa MOLINARI Edivaldo Domingues VELINI Eduardo Romano de Campos PINTO Maria Lucia Zaidan DAGLI Galdino ANDRADE FILHO Patricia Machado Bueno FERNANDES | 2020 | Frontiers of Agricultural Science and Engineering2020，7，2： | 5 |
| 8 | Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients显示文摘AIM:To investigate whether the evaluation of tumor budding can complement K-RAS analysis to improve the individualized prediction of response to anti-epidermal growth factor receptor based therapies in metastatic colorectal cancer (mCRC) patients. METHODS:Forty-three patients with mCRC treated with cetuximab or panitumumab were entered into this study. According to the Response Evaluation Criteria in Solid Tumors criteria, 30 patients had stable or progressive disease (non-responsive), while 13 patients had a partial response. Tumor buds were evaluated from whole tissue sections stained for pan-cytokeratin, evaluated in the densest region using a 40 × objective and 'high-grade' tumor budding was defi ned as 15 buds/high-power f ield.RESULTS: Tumor buds and K-RAS mutation both correctly classif ied 68% of patients. All patients with K-RAS mutation (n=7) or high-grade tumor budding (n=11) were non-responsive, of which 4 patients had both features. All 13 partial responders were K-RAS wild-type with low-grade tumor budding. Combined, the predictive value of K-RAS and tumor budding was 80%. Additionally, high-grade tumor budding was significantly related to worse progression-free survival [HR (95% CI): 2.8 (1.3-6.0, P=0.008)].CONCLUSION: If confirmed in larger cohorts, the addition of tumor budding to K-RAS analysis may represent an effective approach for individualized patient management in the metastatic setting. | Inti Zlobec Francesca Molinari Vittoria Martin Luca Mazzucchelli Piercarlo Saletti Rosangela Trezzi Sara De Dosso Tatjana Vlajnic Milo Frattini Alessandro Lugli | 2010 | World Journal of Gastroenterology2010，16，38： | 4 |
| 9 | Neoadjuvant therapy for resectable pancreatic cancer显示文摘The use of neoadjuvant therapies has played a major role for borderline resectable and locally advanced pancreatic cancers(PCs). For this group of patients, preoperative chemotherapy or chemoradiation has increased the likelihood of surgery with negative resection margins and overall survival. On the other hand, for patients with resectable PC, the main rationale for neoadjuvant therapy is that the overall survival with current strategies is unsatisfactory. There is a consensus that we need new treatments to improve the overall survival and quality of life of patients with PC. However, without strong scientific evidence supporting the theoretical advantages of neoadjuvant therapies, these potential benefits might turn out not to be worth the risk of tumors progression while waiting for surgery. The focus of this paper is to provide the readers an overview of the most recent evidence on this subject. | Sheikh Hasibur Rahman Robin Urquhart Michele Molinari | 2017 | World Journal of Gastrointestinal Oncology2017，9，12： | 4 |
| 10 | Dry sliding wear of Ti–6Al–4V alloy as influenced by the counterface and sliding conditions显示文摘 | G Straffelini A Molinari | 1999 | Wear1999，，1： | 3 |
| 11 | Obesity and liver transplantation显示文摘The percentage of overweight and obese patients(OPs) waiting for a liver transplant continues to increase. Despite the significant advances occurred in bariatric medicine, obesity is still considered a relative contraindication to liver transplantation(LT). The main aim of this review is to appraise the literature on the outcomes of OPs undergoing LT, treatments that might reduce their weight before, during or after surgery, and discuss some of the controversies and limitations of the current knowledge with the intent of highlighting areas where future research is needed. | Subhashini Ayloo John Armstrong Scott Hurton Michele Molinari | 2015 | World Journal of Transplantation2015，5，3： | 3 |
| 12 | Pancreatic fistula: definition and current problems显示文摘 | Giovanni Butturini Despoina Daskalaki Enrico Molinari Filippo Scopelliti Andrea Casarotto Claudio Bassi | 2008 | Journal of Hepato - Biliary - Pancreatic Surgery2008，，3： | 3 |
| 13 | Evidence-Based Approach to Cholangiocarcinoma: A Systematic Review of the Current Literature显示文摘 | Murad Aljiffry Alhawsawi Abdulelah Mark Walsh Kevork Peltekian Ian Alwayn Michele Molinari | 2008 | Journal of the American College of Surgeons2008，，1： | 3 |
| 14 | Oxidation behaviour of ledeburitic steels for hot rolls显示文摘 | A Molinari G Straffelini A Tomasi A Biggi G Corbo | 2000 | Materials Science & Engineering A2000，，2： | 2 |
| 15 | Discrimination between active and inactive neurocysticercosis by metacestode excretory/secretory antigens of Taenia solium in an enzymelinked immunosorbent assay 显示文摘 | Molinari J L Garc i a-Mendoza E de la Garza Y | 2002 | Am J Trop Med Hyg2002，66，6： | 1 |
| 16 | Role of tryptase in immediate cutaneous responses in allergic sheep显示文摘 | Moore WR Clark J | 1995 | J Appl Physiol1995，79，： | 1 |
| 17 | Surface durability of electroless Ni-P composite deposits显示文摘 | D Colombo A Molinari | 1999 | Wear1999，236，1： | 1 |
| 18 | Photocatalytic membrane reactor for degradation of organic pollutants in water 显示文摘 | Molinari R Grande C Drioli E | 2001 | Catalysis Today2001，67，13： | 1 |
| 19 | Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘 | Di Nicolantonio F Martini M Molinari F | 2008 | J Clin Oneol2008，26，35： | 1 |
| 20 | Ca2+-activated neutral protease is active in the erythrocyte membrane in its non-autolyzed 80 kDa form显示文摘 | Molinari M Carafoli E | 1994 | J Biol Chem1994，269，27： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员